Table 2.
Expression | Normal (n = 25) |
Benign (n = 23) |
Cancer (n = 73) |
---|---|---|---|
VDR - Nuclear | |||
0–50 | 20 (80.0) | 17 (73.9) | 31 (42.5) **/# |
51–100 | 5 (20.0) | 6 (26.1) | 42 (57.5) |
VDR - Cytoplasmic | |||
0–50 | 25 (100.0) | 23 (100.0) | 56 (76.7) **/# |
51–100 | 0 (0.0) | 0 (0.0) | 17 (23.3) |
CYP27B1 | |||
Negative | 12 (48.0) | 11 (47.8) | 24 (32.9) |
Positive | 13 (52.0) | 12 (52.2) | 49 (67.1) |
CYP24A1 | |||
Negative | 22 (88.0) | 21 (91.3) | 62 (84.9) |
Positive | 3 (12.0) | 2 (8.7) | 11 (15.1) |
P21 - nuclear | |||
0–10 | 24 (96.0) | 22 (95.7) | 43 (58.9) **/## |
11–100 | 1 (4.0) | 1 (4.3) | 30 (41.1) |
P21 - cytoplasmic | |||
Negative | 22 (88.0) | 22 (95.7) | 64 (87.7) |
Positive | 3 (12.0) | 1 (4.3) | 9 (12.3) |
E-cadherin | |||
Negative | 21 (84.0) | 18 (78.3) | 35 (47.9) **/# |
Positive | 4 (16.0) | 5 (21.7) | 38 (52.1) |
Values are expressed as number (%).
**p < 0.01 versus normal, #p < 0.05 and ##p < 0.01 versus benign.
VDR, vitamin D receptor.